Paper29381964
Treatment of aggressive prolactinoma with temozolomide: A case report and review of literature up to date.
Chen C and 6 others. Medicine (Baltimore), 2017. Cited by 18 papers, by iCite.
Cite this record
ConductScience Library. Treatment of aggressive prolactinoma with temozolomide: A case report and review of literature up to date. Papers, record 29381964. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/29381964
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- Treatment of aggressive prolactinoma with temozolomide: A case report and review of literature up to date.
- PubMed
Topics10
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Antineoplastic Agents, Alkylating | Major topic |
| Dacarbazine | Major topic |
| Pituitary Neoplasms | Major topic |
| Prolactinoma | Major topic |
| Adolescent | |
| Humans | |
| Male | |
| Prolactin | |
| Salvage Therapy | |
| Temozolomide |
Source PubMed
References41
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 22404748 | Pituitary carcinomas and aggressive pituitary tumours: merits and pitfalls of temozolomide treatment. | Clin Endocrinol (Oxf) | 2012 | https://conductscience.org/library/papers/22404748 | PubMed |
| 2 | 14762579 | Measurement of Ki-67 antigen in 159 pituitary adenomas using the MIB-1 monoclonal antibody. | Braz J Med Biol Res | 2004 | https://conductscience.org/library/papers/14762579 | PubMed |
| 3 | 10022862 | Regulation of p53 function and stability by phosphorylation. | Mol Cell Biol | 1999 | https://conductscience.org/library/papers/10022862 | PubMed |
| 4 | 24821329 | Aggressive pituitary adenomas--diagnosis and emerging treatments. | Nat Rev Endocrinol | 2014 | https://conductscience.org/library/papers/24821329 | PubMed |
| 5 | 16328518 | The new WHO classification of pituitary tumors: highlights and areas of controversy. | Acta Neuropathol | 2006 | https://conductscience.org/library/papers/16328518 | PubMed |
| 6 | 22419713 | Expression of Ki-67, PTTG1, FGFR4, and SSTR 2, 3, and 5 in nonfunctioning pituitary adenomas: a high throughput TMA, immunohistochemical study. | J Clin Endocrinol Metab | 2012 | https://conductscience.org/library/papers/22419713 | PubMed |
| 7 | 19654234 | Temozolomide treatment of a pituitary carcinoma and two pituitary macroadenomas resistant to conventional therapy. | Eur J Endocrinol | 2009 | https://conductscience.org/library/papers/19654234 | PubMed |
| 8 | 21745538 | O(6)-Methylguanine-DNA methyltransferase (MGMT) in normal tissues and tumors: enzyme activity, promoter methylation and immunohistochemistry. | Biochim Biophys Acta | 2011 | https://conductscience.org/library/papers/21745538 | PubMed |
| 9 | 21918831 | Anti-VEGF therapy in pituitary carcinoma. | Pituitary | 2012 | https://conductscience.org/library/papers/21918831 | PubMed |
| 10 | 15741248 | Clinical review: Diagnosis and management of pituitary carcinomas. | J Clin Endocrinol Metab | 2005 | https://conductscience.org/library/papers/15741248 | PubMed |
| 11 | 27916892 | Molecular Mechanisms of p53 Deregulation in Cancer: An Overview in Multiple Myeloma. | Int J Mol Sci | 2016 | https://conductscience.org/library/papers/27916892 | PubMed |
| 12 | 20496311 | SOM230 (pasireotide) and temozolomide achieve sustained control of tumour progression and ACTH secretion in pituitary carcinoma with widespread metastases. | Exp Clin Endocrinol Diabetes | 2010 | https://conductscience.org/library/papers/20496311 | PubMed |
| 13 | 20469984 | Temozolomide-induced inhibition of pituitary adenoma cells. | J Neurosurg | 2011 | https://conductscience.org/library/papers/20469984 | PubMed |
| 14 | 8692397 | p53 expression in pituitary adenomas and carcinomas: correlation with invasiveness and tumor growth fractions. | Neurosurgery | 1996 | https://conductscience.org/library/papers/8692397 | PubMed |
| 15 | 22818211 | Temozolomide and unusual indications: review of literature. | Cancer Treat Rev | 2013 | https://conductscience.org/library/papers/22818211 | PubMed |
| 16 | 26614517 | Temozolomide therapy in patients with aggressive pituitary adenomas or carcinomas. | J Neurooncol | 2016 | https://conductscience.org/library/papers/26614517 | PubMed |
| 17 | 21715538 | Pituitary carcinoma with malignant growth from first presentation and fulminant clinical course--case report and review of the literature. | J Clin Endocrinol Metab | 2011 | https://conductscience.org/library/papers/21715538 | PubMed |
| 18 | 26106414 | Temozolomide Therapy for Aggressive Pituitary Tumors: Results in a Small Series of Patients from Argentina. | Int J Endocrinol | 2015 | https://conductscience.org/library/papers/26106414 | PubMed |
| 19 | 23365123 | DNA mismatch repair protein (MSH6) correlated with the responses of atypical pituitary adenomas and pituitary carcinomas to temozolomide: the national cooperative study by the Japan Society for Hypothalamic and Pituitary Tumors. | J Clin Endocrinol Metab | 2013 | https://conductscience.org/library/papers/23365123 | PubMed |
| 20 | 19846904 | p53-Mediated down-regulation of the human DNA repair gene O6-methylguanine-DNA methyltransferase (MGMT) via interaction with Sp1 transcription factor. | Anticancer Res | 2009 | https://conductscience.org/library/papers/19846904 | PubMed |
Cited by13
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 18 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 41793533 | Aggressive and malignant pituitary tumours: does the sex matter? | Pituitary | 2026 | https://conductscience.org/library/papers/41793533 | PubMed |
| 40626090 | Prolactinoma Resection in a Transgender Woman on Gender-affirming Hormone Therapy. | JCEM Case Rep | 2025 | https://conductscience.org/library/papers/40626090 | PubMed |
| 40457103 | Effect of antineoplastic drug therapies on carcinoma and aggressive pituitary tumors: a systematic review and meta-analysis. | Pituitary | 2025 | https://conductscience.org/library/papers/40457103 | PubMed |
| 38370355 | Prolactin-secreting pituitary adenomas: male-specific differences in pathogenesis, clinical presentation and treatment. | Front Endocrinol (Lausanne) | 2024 | https://conductscience.org/library/papers/38370355 | PubMed |
| 37529607 | Therapeutic response to pazopanib: case report and literature review on molecular abnormalities of aggressive prolactinomas. | Front Endocrinol (Lausanne) | 2023 | https://conductscience.org/library/papers/37529607 | PubMed |
| 35865778 | Aggressive prolactinomas responsive to temozolomide treatment: Report of two cases. | Clin Case Rep | 2022 | https://conductscience.org/library/papers/35865778 | PubMed |
| 35059545 | Temozolomide Nonresponsiveness in Aggressive Prolactinomas and Carcinomas: Management and Outcomes. | J Endocr Soc | 2022 | https://conductscience.org/library/papers/35059545 | PubMed |
| 34975752 | Early Initiation of Temozolomide Therapy May Improve Response in Aggressive Pituitary Adenomas. | Front Endocrinol (Lausanne) | 2021 | https://conductscience.org/library/papers/34975752 | PubMed |
| 34934445 | Aggressive prolactinoma (Review). | Exp Ther Med | 2022 | https://conductscience.org/library/papers/34934445 | PubMed |
| 34268462 | Giant Prolactinoma Presenting With Facial Nerve Palsy and Hemiparesis. | J Endocr Soc | 2021 | https://conductscience.org/library/papers/34268462 | PubMed |
| 34195524 | Long-Term Use of Temozolomide as Safe and Effective Therapy for an Aggressive Corticotroph Adenoma in a Very Old Patient. | J Endocr Soc | 2021 | https://conductscience.org/library/papers/34195524 | PubMed |
| 32232709 | Long-course temozolomide in aggressive pituitary adenoma: real-life experience in two tertiary care centers and review of the literature. | Pituitary | 2020 | https://conductscience.org/library/papers/32232709 | PubMed |
| 31522358 | Dopamine agonist resistant prolactinomas: any alternative medical treatment? | Pituitary | 2020 | https://conductscience.org/library/papers/31522358 | PubMed |
Genes7
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
| Gene | NCBI Gene ID | Linked by | In Genes | Source |
|---|---|---|---|---|
| GH1 | 2688 | PubTator's text mining | https://conductscience.org/library/genes/2688 | NCBI Gene |
| MGMT | 4255 | PubTator's text mining | https://conductscience.org/library/genes/4255 | NCBI Gene |
| MSH6 | 2956 | PubTator's text mining | https://conductscience.org/library/genes/2956 | NCBI Gene |
| POMC | 5443 | PubTator's text mining | https://conductscience.org/library/genes/5443 | NCBI Gene |
| PRL | 5617 | PubTator's text mining | https://conductscience.org/library/genes/5617 | NCBI Gene |
| TP53 | 7157 | PubTator's text mining | https://conductscience.org/library/genes/7157 | NCBI Gene |
| VEGFA | 7422 | PubTator's text mining | https://conductscience.org/library/genes/7422 | NCBI Gene |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/29381964
GET https://conductscience.org/api/papers/v1/29381964/references?page=2